Evotec将以3亿美元现金加特许权使用费的价格将Just-Evotec Biologics图卢兹工厂出售给Sandoz，标志着转向资产更轻的模式

2025-07-30 14:54

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz
Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technology
The deal terms include the purchase price of the site for around US$ 300 m in cash, and in addition will include further technology related consideration, future development revenues, milestones and product royalties
Planned transaction marks major milestone in Evotec's strategy to create asset-lighter business model leveraging high-margin offerings, with Just - Evotec Biologics remaining core business for Evotec
Transaction is expected to immediately improve Evotec's short-, mid-, and long-term revenue mix, profit margins, and capital efficiency